Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul-Aug;48(4):609-622.
doi: 10.1590/S1677-5538.IBJU.2021.0560.

VI-RADS score system - A primer for urologists

Affiliations
Review

VI-RADS score system - A primer for urologists

Refky Nicola et al. Int Braz J Urol. 2022 Jul-Aug.

Abstract

Bladder cancer (BCa) is one of the most common cancers worldwide and is also considered to be one of the most relapsing and aggressive neoplasms. About 30% of patients will present with muscle invasive disease, which is associated with a higher risk for metastatic disease. The aim of this article is to review the state of art imaging in Radiology, while providing a complete guide to urologists, with case examples, for the rationale of the development of the Vesical Imaging Reporting and Data System (VI-RADS), a scoring system emphasizing a standardized approach to multiparametric Magnetic Resonance Imaging (mpMRI) acquisition, interpretation, and reporting for BCa. Also, we examine relevant external validation studies and the consolidated literature of mpMRI for bladder cancer. In addition, this article discusses some of the potential clinical implications of this scoring system for disease management and follow-up.

Keywords: Diffusion Magnetic Resonance Imaging; Genitourinary Tract Anomalies [Supplementary Concept]; Urinary Bladder Neoplasms.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Figure 1
Figure 1. These pictures illustrate how structural categories (T2 images) of VI-RADS are assigned. The muscularis propria is presented as a thick black layer. The inner layer (urothelium + lamina propria) is a thin white layer. The tumors are shown in grey and the stalk, when present, in black, in continuity with the muscular layer. The inner layer is preserved in categories 1 and 2. In category 3, the inner layer is not seen, but there is no clear sign of muscle invasion. In categories 4 and 5, the tumors have extended to the muscular layer, and in VI-RADS 5, they go beyond, until perivesical fat.
Figure 2
Figure 2. A 72-year-old woman presented with macroscopic hematuria. A) T2W image (axial plane) shows a large stalked mass at the anterior bladder wall. B and C) DWI (b=2000) and ADC maps show significantly restricted diffusion, not extending through the muscularis propria; the “inchworm” sign can be appreciated. D) DCE imaging shows early and heterogeneous enhancement of the lesions, not extending through the muscularis propria. The final VI-RADS score was 2. T2W, T2 weighted; DCE, dynamic contrast-enhanced; DWI, diffusion-weighted image; ADC, apparent diffusion coefficient.
Figure 3
Figure 3. A 46-year-old, female, complains of frequency, urgency, and severe incontinence. A pelvic sonogram showed moderate to marked left hydronephrosis and asymmetric bladder wall thickening on the top portion of her bladder. A and B) Axial and Coronal T2-weighted MRI of the pelvis demonstrates a 4.4 x 3.6cm mass extending to muscle layer. C) ADC map in the axial plane, and D) T1 post-contrast, also in the axial plane, confirming that mass shows extension into the muscular layer. This was consistent with VI-RADS 4, confirmed after surgery.
Figure 4
Figure 4. The decision algorithm for VI-RADS. When all categories are coincident, the final score is directly assigned. When classification in different sequences is discordant, DCE, and DWI are the dominant sequences and will prevail for the final classification. As seen in figure 4, DCE and DWI can upgrade or downgrade the initial classification found on T2 images.

Comment in

References

    1. Zang Y , Li X , Cheng Y , Qi F , Yang N . An overview of patients with urothelial bladder cancer over the past two decades: a Surveillance, Epidemiology, and End Results (SEER) study . Ann Transl Med . 2020 ; 8 : 1587 . - PMC - PubMed
    1. Bray F , Ferlay J , Soerjomataram I , Siegel RL , Torre LA , Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries . CA Cancer J Clin . 2018 ; 68 : 394 - 424 . Erratum in: CA Cancer J Clin. 2020; 70:313 . - PubMed
    1. Mallin K , David KA , Carroll PR , Milowsky MI , Nanus DM . Transitional cell carcinoma of the bladder: racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007) . J Urol . 2011 ; 185 : 1631 - 6 . - PubMed
    1. Al-Husseini MJ , Kunbaz A , Saad AM , Santos JV , Salahia S , Iqbal M , et al . Trends in the incidence and mortality of transitional cell carcinoma of the bladder for the last four decades in the USA: a SEER-based analysis . BMC Cancer . 2019 ; 19 : 46 . - PMC - PubMed
    1. Burger M , Catto JW , Dalbagni G , Grossman HB , Herr H , Karakiewicz P , et al . Epidemiology and risk factors of urothelial bladder cancer . Eur Urol . 2013 ; 63 : 234 - 41 . - PubMed

MeSH terms